Recently it was announced that CA4P, an ovarian cancer treatment investigation drug of Mateon Therapeutics, was showing favorable results when combined with Roche’s Avastin, (bevacizumab) in a focus study assessing the effectiveness of the combination drugs along with chosen chemotherapy treatment in treating patients with prOC or platinum resistant ovarian cancer.

According to reports, CA4P (combretastatin A-4 phosphate) targets the vasculature of cancer tumors causing central necrosis and is a microtubule destabilizing drug that is very potent. One of the study’s purposes is to establish whether the addition of this investigational drug enhances progression-free survival, the main goal of the study.

So far in the study it appears that, in patients receiving CA4P, there have been favorable results, with the median progression-free survival rate increasing by 1.68 months when compared to patients receiving placebo treatments, in addition to the current standard-of-care for prOC, in conjunction with chemotherapy.

While phase 2 of the trial involved 91 patients who were recruited, the current interim analysis secured these results from the initial 40 patients involved in the study who were treated for a minimum of two months or withdrawn from the trial. Dr. William Schwieterman, CEO and President of Mateon Therapeutics said, “We are encouraged that early data on the primary endpoint of the study continue to favor CA4P and that our investigational drug remains well tolerated.”

REA JET is a leading global supplier of pharma marking and coding solutions for every need. When it comes to reliability, concise marking and cost-effectiveness, trust REA JET for the right pharmaceutical coding technology.